lamyropsis/infarction

To date, there are no drugs or other therapeutics approved by the U.S. Food and Drug Administration (FDA) to prevent or treat COVID-19 that has spread globally resulting in the ongoing pandemic as declared by the World Health Organization (WHO) on 11 March 2020. While the majority of patients have

This is an open-label single-dose study. Approximately 40 total subjects will be enrolled. In each of the 3 hepatic impairment groups (mild hepatic dysfunction [Child-Pugh score of 5 - 6], moderate hepatic dysfunction [Child-Pugh score of 7 - 9], severe hepatic dysfunction [Child Pugh score of 10 -